Ποια είναι η τιμή για ZIOPHARM Oncology, Inc. (ZIOP)

Η τιμή για ZIOPHARM Oncology, Inc. (ZIOP) είναι $0.8657

Ποια είναι η κεφαλαιοποίηση αγοράς για ZIOPHARM Oncology, Inc. (ZIOP)

Η κεφαλαιοποίηση αγοράς για ZIOPHARM Oncology, Inc. (ZIOP) είναι $122.22M

ZIOPHARM Oncology, Inc. (ZIOP) Τιμή και Κεφαλαιοποίηση Αγοράς

ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative immuno-oncology treatments for cancer patients. The company leverages its proprietary Sleeping Beauty platform, which employs non-viral genetic engineering to modify T-cells outside the body using a transposon/transposase system for subsequent infusion. Additionally, ZIOPHARM is advancing its Controlled IL-12 technology, designed to precisely regulate the expression of interleukin-12 (IL-12), a key immune system regulator, to direct the patient's immune response against cancer cells. Its pipeline features several promising therapeutic candidates, including T-cell receptor (TCR) plus T-cell therapies aimed at solid tumors, chimeric antigen receptor (CAR) T-cell therapies specifically targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 combined with veledimex, a gene delivery system for controlled IL-12 production under investigation for treating recurrent adult glioblastoma multiforme. ZIOPHARM maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., and research and development agreements, alongside patent licensing, with institutions such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute. The company's headquarters are located in Boston, Massachusetts.

Η τιμή για ZIOP	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$36,911.68 $122.22M	NVDA	$5.211T	+4,263,695.77%
$32,204.21 $122.22M	AAPL	$4.547T	+3,719,919.96%
$29,482.46 $122.22M	GOOG	$4.162T	+3,405,521.01%
$25,447.43 $122.22M	MSFT	$3.593T	+2,939,420.54%
$19,781.55 $122.22M	AMZN	$2.793T	+2,284,935.02%

Η τιμή για ZIOP

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$36,911.68 $122.22M